Results 41 to 50 of about 24,588 (279)
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson +12 more
wiley +1 more source
ABSTRACT Background Chronic spontaneous urticaria (CSU) is a mast cell‐driven condition defined by recurrent wheals and/or angioedema lasting over 6 weeks without an identifiable trigger. Though CSU is known to co‐occur with atopic diseases and share Th2‐dominant immunologic pathways, prior studies have not adequately addressed these relationships in ...
Julian A. Cortes +4 more
wiley +1 more source
Hair loss is a rare adverse reaction associated with omalizumab, with limited literature reports. The incidence, underlying mechanisms, and clinical characteristics of omalizumab-associated hair loss have not been clarified.
Qian Wang +6 more
doaj +1 more source
Appropriate selection for omalizumab treatment in patients with severe asthma?
Background: Omalizumab improves asthma control in patients with uncontrolled severe allergic asthma; however, appropriate patient selection is crucial. Information in this field is sparse.
Leo Nygaard +3 more
doaj +1 more source
Allergens, germs and asthma [PDF]
Objective To explore asthma pathogenesis using data from upper and lower airways. Data Source English-language papers on human asthma and nasal polyp subjects from 1990 onwards.
Scadding, GK
core
Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria. [PDF]
BACKGROUND: Chronic spontaneous urticaria (CSU) negatively impacts patient quality of life and productivity and is associated with considerable indirect costs to society.
Agirrezabal, I. +9 more
core +1 more source
Elizabeth A Brooks,1 Marc Massanari,2 Nicola A Hanania,3 Daniel J Weiner11TTi Health Research & Economics, Health Research & Economics, Westminster, MD, USA; 2Circassia Pharmaceuticals, Global Medical Affairs, Morrisville, NC, USA; 3Section of ...
Brooks EA +3 more
doaj
Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma [PDF]
Objetivo: Mepolizumab está indicado como tratamiento adicional del asma eosinofílica refractaria grave. Las diferencias observadas en subgrupos poblacionales según recuento eosinofílico plasmático, existencia de pacientes con altos niveles de ...
Alarcón de la Lastra Romero, Catalina +4 more
core +3 more sources
Abstract Objective Previous studies have suggested a benefit to early functional endoscopic sinus surgery (FESS) for chronic rhinosinusitis (CRS). With the approval of T2 biologics for CRS with nasal polyps (CRSwNP), it is important to re‐evaluate FESS timing in relation to T2 biologic utilization.
Radhika Duggal +4 more
wiley +1 more source
Bronchial thermoplasty : a new therapeutic option for the treatment of severe, uncontrolled asthma in adults [PDF]
Bronchial thermoplasty is a young yet promising treatment for severe asthma whose benefit for long-term asthma control outweighs the short-term risk of deterioration and hospitalisation in the days following the treatment.
Alagha, Khuder +10 more
core +5 more sources

